Q3 2024 Apyx Medical Corp Earnings Call Transcript
Key Points
- Apyx Medical Corp (APYX) announced a strategic restructuring to streamline operations and focus resources, which is expected to extend their financial runway into 2027.
- The company reported a 9% growth in disposable handpiece revenue overall and 15% growth in the United States, indicating strong demand for their consumable products.
- Apyx Medical Corp (APYX) is in the final stages of developing the Aon body contouring system, which integrates multiple technologies into a single device, potentially positioning the company as a leader in surgical aesthetics.
- The company received a $7 million direct cash investment from Manta Harla Capital Management, strengthening its balance sheet and validating the potential of its technology.
- Apyx Medical Corp (APYX) has launched a direct-to-consumer strategy to increase awareness of its Renuvion technology, leveraging key influencers and lifestyle expos to boost visibility.
- Total revenue for the third quarter decreased by 4% year-over-year, primarily due to a 6% decline in sales of advanced energy products.
- The company reduced its US workforce by nearly 25% as part of its restructuring efforts, indicating significant operational changes and potential impacts on employee morale.
- Apyx Medical Corp (APYX) reported a net loss attributable to shareholders of $4.7 million, slightly higher than the previous year's loss of $4.6 million.
- The company is facing macroeconomic challenges, including the impact of GLP-1 drugs on procedural volumes, which is expected to continue affecting capital equipment sales.
- Gross profit margin decreased to 60.5% from 66.6% in the prior year period, driven by a decrease in the average selling price of generators and changes in sales mix.
Ladies and Gentlemen. Good morning and welcome to the Apyx Medical Third Quarter, 2024 earnings conference call at this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star and zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jeremy Feffer from Lifesci advisors. Please go ahead.
Thank you and welcome everyone to our third quarter. 2024 earnings call representing the company on the call are Stavros Visian Ais, executive Chairman of the Apex Board of Directors will participate in the first part of the call. Charlie Goodwin, Chief Executive Officer and Matt Hill, Chief Financial Officer of Apex.
Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management and involve
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
